Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 197

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 7
Chunk 197
---
ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS

A. Major Shareholders

The following table sets forth information with
respect to the beneficial ownership of our ordinary Common Shares as of October 31, 2024 by:

  each person or entity known by us to own beneficially  

  each of our directors and executive officers individually;  

  all of our directors and executive officers as a group.  

The beneficial ownership of our Common Shares
is determined in accordance with the rules of the SEC and generally includes any shares over which a person exercises sole or shared
voting or investment power, or the right to receive the economic benefit of ownership. For purposes of the table below, we deem options
and RSUs that are currently exercisable or exercisable within 60 days of October 31, 2024 to be outstanding and to be beneficially owned
by the person holding the options for the purposes of computing the percentage ownership of that person, but we do not treat them as
outstanding for the purpose of computing the percentage ownership of any other person. Percentage of shares beneficially owned is based
on 4,254,186 Common Shares issued and outstanding as of October 31, 2024.

As of January 21, 2025, there were 71 holders of record of our Common
Shares, out of which 5 holders of record had a registered address in the United States. To our knowledge, other than as disclosed in the
table below, our other filings with the SEC and this Annual Report, there has been no significant change in the percentage ownership held
by any major shareholder during the past three years. Except where otherwise indicated, we believe, based on information furnished to
us by such owners, that the beneficial owners of the Common Shares listed below have sole investment and voting power with respect to
such Common Shares.

All of our shareholders, including the shareholders
listed below, will have the same voting rights attached to their Common Shares, and neither our principal shareholders nor our directors
and executive officers will have different or special voting rights with respect to their Common Shares. A description of any material
relationship that our principal shareholders have had with us or any of our predecessors or affiliates within the past three years is
included under “ Related Party Transactions.”

Unless otherwise noted below, the address of each
shareholder, director and executive officer is c/o Clearmind Medicine Inc., 101 - 1220 West 6thAvenue, Vancouver, British